필리핀 대통령궁은 강제 노동을 용납하지 않는다는 입장을 밝히며 미국 무역대표부(USTR)가 제안한 추가 관세 부과 계획을 거부했다.
이번 발표는 USTR이 강제 노동과 관련된 수입 정책이 미국 상거래에 부당하고 부담을 준다고 판단한 60개 경제국 중 하나로 필리핀을 지목한 이후에 나왔다. 클레어 카스트로 대통령궁 공보관은 정부가 강제 노동 관행을 규탄하며 이를 척결하기 위한 관련 법을 시행하고 있다고 밝혔다. 카스트로 공보관은 또한 USTR 보고서를 검토 중이라고 덧붙였다. 정부는 적절한 외교 채널을 통해 미국 측과 소통할 예정이다. USTR은 강제 노동 수입 금지 조치나 부분적인 규제 체계를 가진 경제국에는 10%, 그 외 국가에는 12.5%의 추가 관세를 부과할 것을 제안한 바 있다.
AI에 의해 보고됨 AI에 의해 생성된 이미지
The U.S. Trade Representative (USTR) has initiated Section 301 investigations into South Korea and 59 other economies for failing to adequately ban imports of goods produced with forced labor. This move comes as the Donald Trump administration seeks to introduce new tariffs to replace country-specific emergency tariffs struck down by the Supreme Court last month. South Korea's government plans to engage in close consultations with the U.S. to safeguard national interests.
The American Colombian Chamber of Commerce warned of possible impacts on Colombian exports following a decision by the Office of the United States Trade Representative.
AI에 의해 보고됨
Following the U.S. Trade Representative's March 12 announcement of Section 301 probes into 60 countries for failing to block forced labour goods, South African exporters are voicing concerns over potential new tariffs. The move aims to sustain trade restrictions as Section 122 emergency duties near expiry.
The U.S. Trade Representative (USTR) is holding public hearings this week in Washington on its Section 301 investigations—launched in March into South Korea, China, Japan, the European Union and 13 others—over structural excess capacity in manufacturing. The hearings could lead to tariffs or other measures. A South Korean official presented Seoul's position on the opening day.
AI에 의해 보고됨
The Donald Trump administration announced on April 2 that it will impose 50 percent tariffs on imported steel, aluminum and copper based on the full value paid by U.S. customers. It also adjusted tariffs on derivative metal products and introduced a 100 percent duty on patented pharmaceuticals not made in the U.S. South Korea and others are exempt from the pharmaceutical tariff.